Skip to main content

Ecraid appoints Evelina Tacconelli as Chief Scientific Officer

Ecraid announces the appointment of Evelina Tacconelli as its new Chief Scientific Officer (CSO).
In her new position, Evelina will join the Ecraid management board and work closely with key scientific and academic opinion leaders to advance clinical research in infectious diseases in Europe. This include the development of scientific policies and strategy, business development and new partnerships, and improving trial design management.

Evelina brings with her a strong scientific track record and leadership experience in infectious diseases research and antimicrobial stewardship. She is currently the head and professor of Infectious Diseases at the University of Verona, director of the Infectious Diseases Section at the Verona University Hospital, and a consultant on infectious diseases research for the University of Tübingen, Germany.

In addition to her roles as Chair of the European Committee for Infection Control (EUCIC) of ESCMID, and a WHO and ECDC consultant for infection control and antimicrobial stewardship, she is also involved in various governmental, EU, and WHO projects such as ORCHESTRA, VERDI, VALUE-Dx, MANTICO, VACCELERATE-Italy, ECRAID-Base, EU-RESPONSE, WHO-Solidarity trial, and the 2023 WHO Priority List for new effective antibiotics.

Evelina is currently a coordinating committee member of Ecraid and will take on her role as CSO with immediate effect.

Ecraid CEO Marc Bonten says, “We are delighted to welcome Evelina to our management board. Evelina is a highly respected scientist with an excellent track record and extensive network. I am confident that she will tremendously enhance our capacity to strengthen our clinical research network in Europe, drive research collaborations, and advance our fight against infectious diseases.”   

Evelina says, “I am honoured and thrilled to take on the role of Chief Scientific Officer at Ecraid. Having been part of the organisation since its inception, I am deeply committed to Ecraid’s mission to establish a permanent, not-for-profit, pan-European clinical research network. This will be a crucial component of Europe’s preparedness and response to infectious diseases threats. I believe that our top priority is to foster collaboration between hospitals and research centres to facilitate the successful and rapid implementation of high-quality clinical trials. By doing so, we can improve the efficacy of therapies for infectious diseases and above all, ensure that all European patients have equal access to cutting-edge medicines.”

For more information, please contact


About Ecraid

The European Clinical Research Alliance on Infectious Diseases (Ecraid) is a not-for profit foundation that advances clinical research in the field of infectious diseases by establishing a long-term, financially self-sustainable, clinical research network in Europe. Headquartered in Utrecht, the Netherlands, Ecraid is the first network of its kind in Europe to offer a single point of access to a pan-European clinical research network for infectious diseases and spans over 1,200 clinical sites and 900 laboratories across 42 countries. For more information, please visit